PT  - JOURNAL ARTICLE
AU  - Y. Meissner
AU  - A. Strangfeld
AU  - N. Costedoat-Chalumeau
AU  - F. Förger
AU  - A. Molto
AU  - M. Wallenius
AU  - R. Fischer-Betz
TI  - FRI0601 The nature and extent of data items collected across european pregnancy registers – first results of the european network of pregnancy registers in rheumatology (EUNEP)
AID  - 10.1136/annrheumdis-2018-eular.3200
DP  - 2018 Jun 01
TA  - Annals of the Rheumatic Diseases
PG  - 824--824
VI  - 77
IP  - Suppl 2
4099  - http://ard.bmj.com/content/77/Suppl_2/824.short
4100  - http://ard.bmj.com/content/77/Suppl_2/824.full
SO  - Ann Rheum Dis2018 Jun 01; 77
AB  - Background There is a high unmet need of robust data on the outcomes of pregnancies and drug safety in various inflammatory rheumatic diseases (IRD). The aims of the European Network of Pregnancy Registers in Rheumatology (EuNeP) are to bring together experts who run pregnancy registers, to define a core data set and to perform concerted data analyses.Objectives To describe data items collected in existing multicentre European pregnancy registers in rheumatology.Methods A comprehensive survey on details of the registers was performed encompassing patient enrolment, inclusion criteria, demographics, disease specific and general outcomes, medical treatment, course and outcome of pregnancy and outcomes of the child. Free text answers were possible for all questions. Questionnaires were sent to the principle investigator(s) of the participating studies. The completed questionnaires were reviewed, and responses were evaluated descriptively. Only data items collected during pregnancy are shown.Results The following registers are involved in the collaboration: EGR2 (France), RePreg (Switzerland), REVNATUS (Norway) and Rhekiss (Germany). All registers collect data prospectively and nationwide. Patients can be included before pregnancy (child wish) or during pregnancy in all registers, and in RePreg also up to week 8 postpartal. Enrolment during pregnancy is possible up to gestation week 12 or thereafter in some specific cases (EGR2), week 20 (Rhekiss) or during complete pregnancy (RePreg and REVNATUS). All registers capture data via IT-based systems, REVNATUS documented on paper until 2016. During pregnancy, data is reported once every trimester by physicians and patients. Current figures, baseline characteristics and included IRD are presented in the table. Most of the data items that are independent of the underlying IRD are collected by all registers (figure 1). However, there are differences in the way data is collected and in the level of details.View this table:Abstract FRI0601 – Figure 1 Figures in the bars represent the numbers of reporting registers.Conclusions Although the registers in this collaboration have similar designs, we found considerable differences in data items collected. In particular, the level of details of documented data and the information on disease-specific characteristics varied. Harmonisation of data collected in pregnancy registers would facilitate collaborative analysis.Acknowledgements This work was supported by a research grant from FOREUM Foundation for Research in Rheumatology.Disclosure of Interest Y. Meissner: None declared, A. Strangfeld: None declared, N. Costedoat-Chalumeau: None declared, F. Förger Grant/research support from: UCB Pharma, Speakers bureau: Mepha, Roche, UCB Pharma, A. Molto: None declared, M. Wallenius: None declared, R. Fischer-Betz: None declared